PEDVAC-iNTS Vaccine Trial
A Phase IIa clinical trial study in Ghana aimed at evaluating the safety, immunogenicity, and optimal dosing of the iNTS-GMMA vaccine in young children. The vaccine targets invasive non-typhoidal Salmonella (iNTS), a major cause of illness and death in sub-Saharan Africa, using GMMA technology developed by GSK. The study includes detailed immune profiling and tests antibiotic resistance of circulating Salmonella strains. It forms part of a larger EU-funded project aimed at advancing vaccine development and building research capacity in endemic regions.